Ketamine + Ts-134 for Healthy Subjects

This trial explores how different doses of ketamine, combined with a new drug called TS-134, affect brain activity in healthy individuals. Participants are divided into three groups receiving low, medium, or high doses of ketamine. Within each group, participants will take either TS-134, another treatment called XT, or a placebo. The study aims to understand the brain's response to these combinations, potentially informing future treatments for mental health issues. Individuals who are generally healthy and can commit to the study schedule might be a good fit for this trial. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

Yes, you must stop taking any psychotropic medications (drugs affecting mood, perception, or behavior) to participate in this trial.

Research has shown that ketamine is generally safe for people, with a wide margin of safety, allowing for safe use even at higher doses. However, about 12% of people may experience "emergence reactions," such as confusion or hallucinations upon waking.

Specific safety studies for TS-134 are not yet available. This trial is in its early phase, so researchers are closely monitoring its safety for people. Early phases often focus on understanding the treatment's safety.

Researchers are excited about this treatment because it pairs ketamine, a fast-acting anesthetic known for its rapid impact on mood, with TS-134 or its alternative, XT, offering a potentially new approach to managing conditions like depression. Unlike traditional antidepressants, which can take weeks to become effective, ketamine can work in just hours. The combination with TS-134 or XT might enhance or prolong these effects, offering hope for faster and possibly more sustained relief. This dual approach could address the urgent need for quicker-acting therapies in mental health.

This trial will evaluate the effects of different doses of ketamine, both alone and combined with TS-134, on mood in healthy subjects. Studies have shown that ketamine can quickly improve mood, particularly in individuals with depression. For example, one study found that within two hours of treatment, depression symptoms decreased by about 57% to 60%, with benefits lasting at least four days. Ketamine effectively reduces symptoms even at lower doses, while higher doses provide greater benefits. Although specific data on TS-134 is limited, combining it with ketamine in this trial might enhance or prolong ketamine's effects. Overall, ketamine has shown promise for rapidly improving mood.¹⁶⁷⁸⁹